In recent years, the introduction of antibodies against programmed cell death protein-1 (PD-1) and its ligand (PDL1) have exhibited effective antitumor activity in non-small-cell lung cancer (NSCLC), with encouraging results [2,3,4,5,6]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.